
    
      In patients with SFJ incompetence due to reflux of the Great Saphenous Vein (GSV) or major
      accessory veins, with venous disease manifested by both symptoms and visible varicosities:
      using duplex ultrasonography, to evaluate the efficacy of VarisolveÂ® 0.125% [0.2%] as
      assessed by the elimination of SFJ reflux and/or occlusion of the treated vein
    
  